commercial expansion

Aclarion appoints Daniel Keefe as Western U.S. Commercial Director to accelerate adoption of its Nociscan diagnostic platform amid triple-digit growth.

Palantir surged 1,600% with 135% revenue growth and newfound profitability, but its 113x forward P/E valuation may have priced in years of future growth already.

Palantir stock has fallen 30% from peaks but remains overvalued at 231x earnings despite 74% revenue growth and record margins, analysts say.

Esperion completes acquisition of Corstasis, adding Enbumyst, first FDA-approved nasal spray loop diuretic, to expand its cardiovascular product portfolio.

Esperion closes Corstasis acquisition, gaining FDA-approved Enbumyst nasal spray loop diuretic for heart failure treatment, leveraging existing cardiovascular commercial infrastructure.

Pulsenmore ($PLSM) reported $12.5M revenue in 2025, up 374% YoY, buoyed by $9.6M GE settlement. FDA clearance for remote prenatal ultrasound and European CE certification enable market expansion.

Palantir demonstrates 70% revenue growth and strong commercial traction via Foundry AIP, but 51.5x forward P/S valuation limits near-term upside despite long-term potential.

Palantir surged 23% in one month on 70% revenue growth and 137% U.S. commercial expansion, but extreme P/E ratio of 255 raises valuation concerns despite solid fundamentals.

Palantir delivers 70% revenue growth with rule of 40 score of 127%, signaling potential bargain despite elevated valuation.

Palantir surged 2,200% since 2023 with 70% revenue growth, but 116x forward earnings valuation—5x Nvidia—may already price in years of gains.

Microbot Medical confirms uninterrupted USA and Israel operations amid geopolitical tensions, accelerating LIBERTY robotic system expansion with planned April 2026 commercial launch.

Palantir surged 11% on strong earnings showing 70% revenue growth, but 80x sales valuation leaves little room for error. Analysts recommend waiting for better entry points.

Palantir reports 70% revenue growth and 79% EPS growth with 137% commercial surge, though 100x P/E valuation leaves limited room for error amid recent 26% pullback.

Orange Bank & Trust promotes Joseph Ruhl to Senior Executive Vice President, recognizing his nine-year track record expanding deposits and business development in Westchester County and Lower Hudson Valley markets.

Harrow Health will release 2025 financial results March 2, 2026, reaffirming $270-$280 million revenue guidance and highlighting its expanding pharmaceutical portfolio.

Palantir's stock surged over 1,300% since its 2020 IPO, with a $10,000 investment growing to $142,820. AI adoption and sector expansion drive continued analyst optimism.